



**DEVELOPMENT OF A FIXED-DOSE COMBINATION
CAPSULE OF CARBAMAZEPINE AND GABAPENTIN**

BY

IRDA HASLINDA BINTI HASSAN

**A thesis submitted in fulfilment of the requirement for the
degree of Master in Pharmaceutical Sciences
(Pharmaceutical Technology)**

**Kulliyyah of Pharmacy
International Islamic University Malaysia**

SEPTEMBER 2018

ABSTRACT

The rate of patient's compliance is markedly reduced as the number of medications and dosing frequency increased. The compliance for the combination of carbamazepine tablet which is twice daily dosing and gabapentin capsule which is given three times daily is greatly affected in painful diabetic peripheral neuropathy patient. This study aim to develop a fixed-dose combination of carbamazepine and gabapentin (FDC CBZ-GBP) in order to simplify the treatment and improve the compliance. Hence, it is important to identify the compatible excipient for both drugs for the purpose of formulation development. Compatibility study was performed on both active pharmaceutical ingredients (API) and each API with several excipients using differential scanning calorimetry (DSC) and supported by attenuated total reflectance-fourier transform infrared spectroscopy (ATR-FTIR). DSC results showed incompatibility between GBP and CBZ, lactose monohydrate, magnesium stearate, talc and hydroxypropyl methylcellulose where the melting peak of GBP significantly shifted. However, ATR spectra of those combinations excluded these incompatibilities. Preliminary lab scale production of FDC CBZ-GBP for 2 kilograms was done with the incorporation of 2 excipients only; namely, lactose and magnesium stearate. The lab scale FDC CBZ-GBP had flow function > 10 , compressibility index $11.73 \pm 2.28\%$ and Hausner ratio 1.13 ± 0.03 which indicated free-flowing powder. Thus, the intended fill weight of $300 \text{ mg} \pm 7.5\%$ can be achieved. The analytical method development (AMD) and analytical method validation (AMV) of FDC CBZ-GBP including specificity, accuracy, precision, intermediate precision, linearity, limit of detection (LOD) and limit of quantification (LOQ) were performed by using HPLC. All the AMV parameters met all the compendial specifications. FDC CBZ-GBP was scaled-up to 24 kilograms to identify optimum processing parameters such as mixing time, mixing direction, dosator speed and dose controller. Based on scale-up results, the optimum mixing time was 52.5 min with 4 clockwise and 2 anticlockwise turns. The expected setting of dosator speed (400 pcs/min) and dose controller (15 mm) for capsule filling process was not stable because process capability index (Cpk) was less than 1. Samples from scale-up process were taken and stored in both real time and accelerated stability chambers for stability study. All stability study parameters including moisture content, assay of carbamazepine and gabapentin, disintegration time and dissolution profile at all-time points met the compendial specifications. In conclusion, FDC CBZ-GBP was successfully developed into a new dosage form of a fixed-dose capsule.

خلاصة البحث

إن معدل التزام المرضى قد تناقص بشكل ملحوظ بزيادة عدد الادوية وعدد الجرعات. الالتزام في اخذ مزيج من حبوب carbamazepine التي تؤخذ مرتين في اليوم وكبسولات gabapentin التي تؤخذ ثلاث مرات يوميا قد تأثر كثيرا عند مرضى اعتلال الاعصاب المحيطية السكري شديد الألم. هذه الدراسة تطمح الى تطوير جرعة ثابتة من مزيج carbamazepine و gabapentin (FDC CBZ- gabapentin GBP) من اجل تبسيط العلاج وتحسين الالتزام. بالتالي فمن المهم تمييز السواغات المتوافقة لكلا الدوائيين لغرض تطوير التركيبة. تم تنفيذ دراسة التوافق على المكونات الصيدلانية الفعالة API لكلا الدوائيين ولكل السواغات باستخدام المسح الحراري التفاضلي DSC ومدعم ب مطيافية الاشعة تحت الحمراء (ATR-FTIR). نتائج DSC أظهرت عدم توافق بين GBP و CBZ, lactose, hydroxylpropyl, talc, magnesium stearate, monohydrate و methylcellulose حيث أن ذروة الانصهار ل GBP قد ازيجت بشكل ملحوظ. ومع ذلك فإن أطياف ATR لتلك التركيبات تستبعد وجود عدم التوافق. النتائج المخبرية الأولية ل FDC CBZ-GBP ل 2 كيلوجرامات قد تمت مع دمج سواغين هما, lactose and magnesium stearate, فقط. قياس الانسيابية كان اقل من 10 و compressibility index, Hausner ratio 1.13 ± 0.03 and $11.73 \pm 2.28\%$ والذي يشير الى انسيابية حرة للمسحوق. وهكذا فإن وزن التحميل المطلوب ل 300 ملجم $\pm 7.5\%$ يمكن تحقيقه. تطوير والتحقق من طريقة التحليل والتي تشمل عدة عوامل كالخطية والدقة وغيرها قد تمت باستخدام HPLC. جميع المعايير استوفت جميع المواصفات الدستورية. تم توسيع الإنتاج الى 24 كجم من اجل تحديد معايير المعالجة المثلى مثل مدة الخلط, اتجاه الخلط ومعاملات آلة التعبئة في الكبسولات. وفقا للنتائج فإن وقت الخلط الأمثل كان 52.5 دقائق مع 4 دورات مع عقارب الساعة ودورتين عكسها. الإعدادات المتوقعة للتعبئة بسرعة 400 كبسولة في الدقيقة ومعامل 15 لالة من اجل عملية ملء الكبسولة لم تكن مستقرة لأن Cpk اقل من 1. تم أخذ عينات من عملية توسيع النطاق وتم حفظها في غرف دراسة الثباتية المسرعة والحقيقية. جميع خصائص دراسة الاستقرار والتي تشمل محتوى الرطوبة, فحص carbamazepine و gabapentin, وقت التفكك و الانحلالية في جميع الأوقات استوفت جميع المواصفات الدستورية. في الختام, تم بنجاح تطوير شكل جرعة جديد من كبسولات ثابتة الجرعة ل FDC CBZ-GBP.

APPROVAL PAGE

I certify that I have supervised and read this study and that in my opinion, it conforms to acceptable standards of scholarly presentation and is fully adequate, in scope and quality, as a thesis for the degree of Master in Pharmaceutical Sciences (Pharmaceutical Technology).

.....
Farahidah binti Mohamed
Supervisor

.....
Abd Almonem Doolanea
Co-Supervisor

.....
Sinan Mohammed Abdullah Al-
Mahmood
Co-Supervisor

I certify that I have read this study and that in my opinion it conforms to acceptable standards of scholarly presentation and is fully adequate, in scope and quality, as a thesis for the degree of Master in Pharmaceutical Sciences (Pharmaceutical Technology).

.....
Bappaditya Chatterjee
Internal Examiner

.....
Mohd Hanif bin Zulfakar
External Examiner

This thesis was submitted to the Department of Pharmaceutical Technology and is accepted as a fulfilment of the requirement for the degree of Master in Pharmaceutical Sciences (Pharmaceutical Technology).

.....
Muhammad Taher bin Bakhtiar
Head, Department of
Pharmaceutical Technology

This thesis was submitted to the Kulliyah of Pharmacy and is accepted as a fulfilment of the requirement for the degree of Master in Pharmaceutical Sciences (Pharmaceutical Technology).

.....
Juliana binti Md. Jaffri
Dean, Kulliyah of Pharmacy

DECLARATION

I hereby declare that this thesis is the result of my own investigations, except where otherwise stated. I also declare that it has not been previously or concurrently submitted as a whole for any other degrees at IIUM or other institutions.

Irda Haslinda binti Hassan

Signature

Date

INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA

**DECLARATION OF COPYRIGHT AND AFFIRMATION OF
FAIR USE OF UNPUBLISHED RESEARCH**

**DEVELOPMENT OF A FIXED-DOSE COMBINATION
CAPSULE OF CARBAMAZEPINE AND GABAPENTIN**

I declare that the copyright holders of this thesis are jointly owned by the student and IIUM.

Copyright © 2018 Irda Haslinda binti Hassan and International Islamic University Malaysia. All rights reserved.

No part of this unpublished research may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without prior written permission of the copyright holder except as provided below

1. Any material contained in or derived from this unpublished research may be used by others in their writing with due acknowledgement.
2. IIUM or its library will have the right to make and transmit copies (print or electronic) for institutional and academic purposes.
3. The IIUM library will have the right to make, store in a retrieved system and supply copies of this unpublished research if requested by other universities and research libraries.

By signing this form, I acknowledged that I have read and understand the IIUM Intellectual Property Right and Commercialization policy.

Affirmed by Irda Haslinda binti Hassan

.....
Signature

.....
Date

ACKNOWLEDGEMENTS

All glory is due to Allah, the Almighty, whose Grace and Mercies have been with me throughout the duration of my programme. Although, it has been tasking, His Mercies and Blessings on me ease the herculean task of completing this thesis.

I am most indebted to my supervisor, Assoc. Prof. Dr Farahidah binti Mohamed, whose enduring disposition, kindness, promptitude, thoroughness and friendship have facilitated the successful completion of my work. I put on record and appreciate her detailed comments, useful suggestions and inspiring queries which have considerably improved this thesis. Her brilliant grasp of the aim and content of this work led to her insightful comments, suggestions and queries which helped me a great deal. Despite her commitments, she took time to listen and attend to me whenever requested. The moral support she extended to me is in no doubt a boost that helped in building and writing the draft of this research work. I am also grateful to my co-supervisor, Asst. Prof. Dr. Abd Almonem and Br. Sinan Mohammed Abdullah Al-Mahmood, whose support and cooperation contributed to the outcome of this work.

Lastly, my gratitude goes to my beloved family and friend; for their prayers and support contributed to the outcome of this work.

Once again, we glorify Allah for His endless mercy on us one of which is enabling us to successfully round off the efforts of writing this thesis. Alhamdulillah.

TABLE OF CONTENTS

Abstract	ii
Abstract in Arabic	iii
Approval page	iv
Declaration	vi
Copy Right	vii
Acknowledgements	viii
Table of contents	ix
List of Tables	xiii
List of Figures	xv
List of Equations	xx
List of Abbreviations	xxi
CHAPTER ONE: INTRODUCTION	1
1.1 Background of the Study	1
1.2 Literature Review	6
1.2.1 Capsule Dosage Form and its Formulation.....	6
1.2.2 Fixed-Dose Combination	8
1.2.3 Carbamazepine: An Overview	10
1.2.4 Carbamazepine: Physicochemical properties.....	13
1.2.5 Gabapentin: An Overview	14
1.2.6 Gabapentin: Physicochemical properties	16
1.2.7 Compatibility Study	17
1.2.8 Analytical Method Development (AMD) and Validation (AMV)	20
1.2.9 Scale-up.....	23
1.3 Problem Statement.....	25
1.4 Research Objectives.....	25
1.5 Research Flow	26
1.6 Chapter Summary	27
CHAPTER TWO: FORMULATION DEVELOPMENT	28
2.1 Introduction.....	28
2.2 Materials	29
2.3 Method.....	31
2.3.1 Compatibility Study	31
2.3.1.1 Thermal Analysis by Differential Scanning Calorimetry (DSC).....	31
2.3.1.2 Screening of Chemical Interaction by Fourier-transform Infrared Spectroscopy (FTIR)	32
2.3.1.3 Morphology by Scanning Electron Microscopy (SEM)...	33
2.3.1.4 Analysis of Percentage Area by High Performance Liquid Chromatography (HPLC).....	33
2.3.1.5 Statistical Analysis	34
2.3.2 Formulation Development	35
2.3.2.1 Preparation of a Fixed-Dose Combination Carbamazepine- Gabapentin Capsule.....	35

2.3.2.2	Characterization of Particle Size and Shape for Raw Materials	37
2.3.2.3	Measurement of Bulk Density and Tapped Density of Raw Materials	39
2.3.2.4	Flow Function Test for Raw Materials	41
2.3.2.5	Lab Scale of a Fixed-Dose Combination Carbamazepine-Gabapentin Capsule	43
2.3.3	Characterization of Lab Scale Batch	45
2.3.3.1	Bulk Density/ Tapped Density/ CI / HR and Target Fill Weight for the Capsule	45
2.3.3.2	Flow Function Test for Lab Scale Batch	46
2.3.3.3	Moisture Content	46
2.3.3.4	Homogeneity Test	46
2.3.3.5	Weight Variation of the Capsule	47
2.3.3.6	Statistical Analysis	48
2.4	Results and Discussion	49
2.4.1	Compatibility Study	49
2.4.1.1	Thermal Analysis by Differential Scanning Calorimetry (DSC)	49
2.4.1.2	Screening of Chemical Interaction by Fourier-transform Infrared Spectroscopy (FTIR)	57
2.4.1.3	Photomicrograph of CBZ and CBZ: GBP/Excipient Mixtures	60
2.4.1.4	Analysis of Percentage Area by High Performance Liquid Chromatography (HPLC)	63
2.4.2	Formulation Development	67
2.4.2.1	Characterization of Particle Size and Shape-Determination for Raw Materials	67
2.4.2.2	Measurement of Bulk Density and Tapped Density of Raw Materials	70
2.4.2.3	Flow Function Test for Raw Materials	72
2.4.3	Characterization of Lab Scale Batch	74
2.4.3.1	Bulk density/ Tapped density/ CI/ HR Target Fill Weight for the Capsule	74
2.4.3.2	Flow Function Test for Lab Scale Batch	76
2.4.3.3	Moisture Content	76
2.4.3.4	Homogeneity Test	77
2.4.3.5	Weight Variation of the Capsule	78
2.5	Conclusion	80

CHAPTER THREE: ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF CARBAMAZEPINE AND GABAPENTIN IN FIXED-DOSE COMBINATION CAPSULE81

3.1	Introduction	81
3.2	Analytical Method Validation of CBZ-GBP Fixed-Dose Combination	83
3.2.1	Materials	83
3.2.1.1	Chemicals and Reagents	83
3.2.1.2	Instrumentation	84
3.2.2	Method Development	85
3.2.2.1	Determination of Suitable Detection Wavelength	85
3.2.2.2	Determination of Mobile Phase and Mode of Elution	85

3.2.3 Method Validation	87
3.2.3.1 Preparation of Solution	87
3.2.3.2 Specificity	88
3.2.3.3 Specificity: Forced Degradation	90
3.2.3.3.1 Acid Degradation	90
3.2.3.3.2 Basic Degradation	90
3.2.3.3.3 Oxidation Degradation	90
3.2.3.3.4 Photo Degradation	91
3.2.3.3.5 Heat Degradation	91
3.2.3.4 Accuracy	91
3.2.3.5 Precision	92
3.2.3.6 Intermediate Precision	92
3.2.3.7 Limit of Detection (LOD) and Limit of Quantification (LOQ)	93
3.2.3.8 Linearity	93
3.3 Results and Discussion	94
3.3.1 Method Development	94
3.3.1.1 Determination of Suitable Detection Wavelength	94
3.3.1.2 Determination of Mobile Phase and Mode of Elution	96
3.3.2 Method Validation	101
3.3.2.1 Specificity	101
3.3.2.2 Specificity: Force Degradation	105
3.3.2.2.1 Acid Degradation	106
3.3.2.2.2 Basic Degradation	107
3.3.2.2.3 Oxidative Degradation	108
3.3.2.2.4 Photo Degradation	109
3.3.2.2.5 Heat Degradation	110
3.3.2.3 Accuracy	112
3.3.2.4 Precision and Intermediate Precision	114
3.3.2.5 Limit of Detection (LOD) and Limit of Quantification (LOQ)	118
3.3.2.6 Linearity	119
3.4 Conclusion	121
CHAPTER FOUR: SCALE-UP AND STABILITY STUDY	122
4.1 Introduction	122
4.2 Scale-up	123
4.2.1 Materials	123
4.2.2 Method	124
4.2.2.1 Determination of Process Parameter for the Mixing Step	124
4.2.2.2 Determination Process Parameter of Capsule Filling	128
4.3 Stability Study	128
4.3.1 Equipment	128
4.3.2 Method	128
4.3.2.1 Procedures	128
4.3.2.2 Characterization	129
4.3.2.2.1 Moisture Content	129
4.3.2.2.2 Assay	129
4.3.2.2.3 Disintegration Time	130
4.3.2.2.4 Dissolution Profile	130
4.4 Results and Discussion	132

4.4.1 Scale-up: Quality Target Product Profile (QTPP), Critical Quality Attributes (CQA) and Critical Process Parameters (CPP)	132
4.4.2 Scale-up: Blend Uniformity	134
4.4.3 Scale-up: Bulk Density/ Tapped Density/ CI/ HR	139
4.4.4 Scale-up: Powder Flow Function	140
4.4.5 Scale-up: Weight Variation	141
4.4.6 Stability: Moisture Content	146
4.4.7 Stability: Assay	148
4.4.8 Stability: Disintegration Time	153
4.4.9 Stability: Dissolution Profile	154
4.5 Conclusion	157

CHAPTER FIVE: GENERAL CONCLUSION AND FUTURE WORKS.....158

5.1 General Conclusion	158
5.2 Recommendation and Future Works	159

REFERENCES.....160

APPENDIX I: ATTENDED CONFERENCE.....176

APPENDIX II: ACCEPTED ABSTRACT FOR CONFERENCE177

APPENDIX III: CERTIFICATE OF ANALYSIS (COA) OF CBZ A178

APPENDIX IV: CERTIFICATE OF ANALYSIS (COA) OF CBZ B.....179

APPENDIX V: CERTIFICATE OF ANALYSIS (COA) OF GBP A180

APPENDIX VI: CERTIFICATE OF ANALYSIS (COA) OF GBP B.....181

APPENDIX VII: CERTIFICATE OF ANALYSIS (COA) OF HARD GELATIN CAPSULE182

LIST OF TABLES

Table 1.1	List of combination drugs for PDPN in various clinical trials.	5
Table 1.2	Summary of some compatibility studies using thermal and non-thermal techniques.	19
Table 1.3	List of parameters and their acceptance criteria in AMV (Huber, 2010; ICHHT, 2005; Shabir, 2004).	21
Table 1.4	Parameters for analytical method validation (non-compendial method) requirements by National Pharmaceutical Regulatory Agency (NPRA), Malaysia.	22
Table 1.5	Analytical method verification requirements for compendial method.	23
Table 2.1	Different classes of excipients for drug-excipient compatibility testing.	32
Table 2.2	List of three manufacturers for three raw materials.	35
Table 2.3	Amount of raw materials needed for 50 unit of size 1 capsules.	37
Table 2.4	Scale of Flowability.	41
Table 2.5	British pharmacopeia specification of capsule percentage deviation.	48
Table 2.6	Sample Coding for Drug-Excipient Studies.	49
Table 2.7	Percentage of peak area of CBZ in drug-drug/excipients mixtures. Percentage of peak area for all binary mixtures were within acceptable range (i.e. 98 to 102%); n=3.	65
Table 2.8	Percentage of peak area of GBP in drug-drug/excipients mixtures. Percentage of peak area for all binary mixtures were within acceptable range (i.e. 98 to 102%); n=3.	66
Table 2.9	Bulk density (ρ_{BD}), tapped density ρ_{TD} , compressibility index (CI), and Hausner ratio (HR) of carbamazepine, gabapentin and lactose. The acceptance criteria for CI and HR is shown in Table 2.4. (B indicates the raw materials were obtained from supplier B).	71
Table 2.10	Flow function factors of the powder mixtures determined by the PFT.	73
Table 2.11	Bulk density (ρ_{BD}), tapped density (ρ_{TD}), Carr index (CI), and Hausner ratio (HR) of same formulation of different source of raw materials. (F-A= Formulation that used the raw materials from	

supplier A, F-B= Formulation that used the raw materials from supplier B).	75
Table 2.12 Result of weight variation.	79
Table 3.1 Peak summary characteristics of system suitability solution extracted from Figure 3.14 (500 µg/mL-1500 µg/mL).	101
Table 3.2 Peak purity of standard CBZ, peak purity of sample CBZ, peak purity of standard GBP and peak purity of sample GBP.	103
Table 3.3 Summary of forced degradation result for Gabapentin (GBP).	111
Table 3.4 Summary of forced degradation result for Carbamazepine (CBZ).	111
Table 3.5 Accuracy/recovery studies.	113
Table 3.6 System suitability test (SST) and precision of FDC CBZ-GBP extracted from Figure 3.14. The % RSDs were highlighted below.	115
Table 3.7 System suitability test (SST) and intermediate precision of FDC CBZ-GBP performed on a different day. The % RSD was highlighted below.	116
Table 3.8 LOD and LOQ of carbamazepine and gabapentin in FDC CBZ-GBP.	118
Table 4.1 List of raw materials of FDC CBZ-GBP.	124
Table 4.2 Duration and direction of V-mixer operation.	125
Table 4.3 Bulk density (ρ_{BD}), tapped density (ρ_{TD}), compressibility index (CI), and Hausner ratio (HR) for batch 1 and the combination of batch 1 and batch 2 samples which taken from 3 sampling points i.e. top, middle and bottom.	140

LIST OF FIGURES

Figure 1.1	Algorithm for Management of Peripheral Diabetic Neuropathy adapted from Vijayan et al. (2012).	4
Figure 1.2	Standard capsule sizes adopted from Nashmir Capsule Sdn Bhd catalogue.	6
Figure 1.3	Decision tree of the formulation design of FDC adapted from Desai et al. (2012).	10
Figure 1.4	Chemical structure of Carbamazepine.	10
Figure 1.5	Metabolism of carbamazepine in the liver adopted from Eichelbaum et al., (1985).	13
Figure 1.6	Chemical structure of Gabapentin.	14
Figure 1.7	Suggested pathway of gabapentin metabolism in the brain adopted from Goldlust et al. (1995).	16
Figure 1.8	Flowchart for the drug-excipient compatibility study adapted from Chadha & Bhandari (2013).	20
Figure 1.9	Example of Ishikawa diagram summarizing critical quality attributes (CQA) for fixed-dose combination of gabapentin and carbamazepine.	24
Figure 1.10	Research flow.	26
Figure 2.1	Capsule filling machine, i.e. card, tamping tool, encapsulator upper part and encapsulator upper part.	37
Figure 2.2	Particle size distribution curve.	38
Figure 2.3	Schematic diagram of powder flow tester (PFT). (Adopted from Brookfield PFT™ catalogue).	42
Figure 2.4	Schematic diagram on the preparation of lab scale-up FDC CBZ-GBP (2 kg). CBZ = carbamazepine, GBP = gabapentin, LAC = lactose and MAS = magnesium stearate.	45
Figure 2.5	Thermogram of CBZ and the binary mixtures.	51
Figure 2.6	Thermogram of GBP and the binary mixtures.	52
Figure 2.7	Thermograms of LAC before grinding (a), LAC after grinding (b).	53

Figure 2.8	Melting point of CBZ and CBZ-drug/excipients mixture. Asterisk (*) indicates significant value ($P < 0.05$) when compared against others individually.	56
Figure 2.9	Melting point of GBP and GBP-drug/excipients mixture. Asterisk (*) indicates significant value ($P < 0.05$) when compared against others individually.	56
Figure 2.10	ATR-FTIR spectra of CBZ and CBZ-drug/excipients mixture.	59
Figure 2.11	ATR-FTIR spectra of CBZMAS (a) 1:0.5 and (b) 1:1 ratio at wavelength range of 4000 cm^{-1} to 400 cm^{-1}	59
Figure 2.12	ATR-FTIR spectra of GBP and GBP-drug/excipients mixture.	60
Figure 2.13	SEM micrographs of (a) CBZ (magnification 300x), (b) CBZLAC (magnification 300x), (c) CBZMAS (magnification 300x), and (d) CBZTALC (magnification 100x); (i) carbamazepine and (ii) excipients such lactose, magnesium stearate and talc.	61
Figure 2.14	SEM micrographs of (a) GBP (rod), (b) GBP (rhombus), (c) GBPLAC (non-grind), (d) GBPLAC (grind) (e) GBPMAS and (f) GBPTALC (the background of the picture is gabapentin and the small particle on gabapentin is talc); magnification for all pictures were 300x.	62
Figure 2.15	Chromatogram of GBP peak at 3.343 min (a) CBZ peak at 16.850 min (b) CBZGBP peak at 2.564 min and 17.960 min (c).	64
Figure 2.16	Particle sizes ($d [v, 10]$, $d [v, 50]$ and $d [v, 90]$) of gabapentin (GBP B), carbamazepine (CBZ B), lactose (LAC B) and magnesium stearate (MAS). Asterisk (***) indicates significant value ($P < 0.05$) when compared according to their particle size distribution i.e: $d [v, 10]$ (blue) of GBP was compared with $d [v, 10]$ of CBZ, LAC and MAS.	68
Figure 2.17	Morphology of carbamazepine (a), gabapentin (b), lactose (c) and magnesium stearate (d) under light microscope.	69
Figure 2.18	Morphology of (a) carbamazepine (magnification 17x), (b) gabapentin (magnification 22x), (c) lactose (magnification 102x) and (d) magnesium stearate (magnification 1000x) using SEM.	70
Figure 2.19	Flow function plots of raw materials from different manufacturers.	73
Figure 2.20	Flow function plot of F-A (formulation A) (grey) and F-B (formulation B) (brown).	76
Figure 2.21	Percentage recovery (%) of carbamazepine and gabapentin after mixing process.	77

Figure 3.1	Chart representing screening of wavelength and its relationship with peak area.	94
Figure 3.2	HPLC Chromatograms of carbamazepine and gabapentin at various wavelength i.e. 190 nm, 195 nm, 200 nm, 205 nm and 210 nm.	95
Figure 3.3	HPLC Chromatograms of carbamazepine and gabapentin at different elution mode i.e. gradient mode and isocratic mode	98
Figure 3.4	HPLC Chromatograms of carbamazepine and gabapentin produced by using different columns i.e. C8 column and C18 column.	99
Figure 3.5	HPLC Chromatograms of carbamazepine and gabapentin eluted by using different ratio of mobile phase i.e. Buffer pH 4: ACN (40:60), (60:40) and (80:20).	100
Figure 3.6	HPLC Chromatograms showing retention time of placebo without any peak (black), carbamazepine WS at 16.932 min (500 µg/mL) and gabapentin WS at 3.599 min (1500 µg/mL) (purple), carbamazepine and gabapentin extracted in FDC CBZ-GBP at 16.922 min and 3.604 min (500 µg/mL and 1500 µg/mL) (blue) and blank without any peaks (green).	102
Figure 3.7	HPLC Chromatograms of peak purity of standard GBP (a), peak purity of sample GBP (b), peak purity of standard CBZ (c) and peak purity of sample CBZ (d).	104
Figure 3.8	HPLC Chromatogram of acid-treated (1.0 N HCl heated for 24 hours at 70°±0.2 °C) GBP and CBZ.	106
Figure 3.9	HPLC Chromatogram of base-treated (1.0 N NaOH heated for 24 hours at 70°±0.2 °C) GBP and CBZ.	107
Figure 3.10	HPLC Chromatogram of hydrogen peroxide (H ₂ O ₂) (30% w/v)-treated GBP and CBZ at 70°±0.2 for 24 hours.	108
Figure 3.11	HPLC Chromatogram of GBP and CBZ following the exposure to ultraviolet light for 24 hours.	109
Figure 3.12	HPLC Chromatogram of GBP and CBZ following exposure to 70°±0.2 °C for 24 hours.	110
Figure 3.13	The concept of accuracy and precision.	113
Figure 3.14	HPLC Chromatograms of system suitability for carbamazepine and gabapentin in FDC CBZ-GBP (500 µg/mL-1500 µg/mL) (n=6).	117
Figure 3.15	Linearity curve of carbamazepine (a) and gabapentin (b) in FDC CBZ-GBP.	120

Figure 4.1	Schematic diagram of industrial scale-up of FDC CBZ-GBP. Adopted from Shanghai Pharmaceutical Machinery Co. Ltd catalogue.	127
Figure 4.2	The alphabets represent the location of sampling point after mixing process. Adopted from Shanghai Pharmaceutical Machinery Co. Ltd catalogue.	127
Figure 4.3	Ishikawa diagram lists the quality target product profile (QTPP) of FDC CBZ-GBP.	133
Figure 4.4	Ishikawa diagram shows the critical quality attribute (CQA) of FDC CBZ-GBP.	134
Figure 4.5	Percentage recovery (%) as assayed by HPLC for carbamazepine and gabapentin for first batch (24 kg) at 60 minute mixing process. CW= clockwise and ACW=anticlockwise. [Carbamazepine: Lower specification limit (LSL) = 92% and Upper specification limit (USL) = 108%]. [Gabapentin: Lower specification limit (LSL) = 90% and Upper specification limit (USL) = 110%].	137
Figure 4.6	Percentage recovery (%) as assayed by HPLC for carbamazepine and gabapentin for second batch (24 kg) at 52.5 minute of mixing process. [Carbamazepine: Lower specification limit (LSL) = 92% and Upper specification limit (USL) = 108%]. [Gabapentin: Lower specification limit (LSL) = 90% and Upper specification limit (USL) = 110%].	138
Figure 4.7	Percentage recovery (%) as assayed by HPLC for carbamazepine and gabapentin for the combined batches at 52.5 minute mixing process (48 kg). [Carbamazepine: Lower specification limit (LSL) = 92% and Upper specification limit (USL) = 108%]. [Gabapentin: Lower specification limit (LSL) = 90% and Upper specification limit (USL) = 110%].	138
Figure 4.8	Flow function plots of pilot scale-up batch 1 (a) and combination of batch 1 and batch 2 (b).	141
Figure 4.9	Average fill weight of the capsule at the speed of 300 pcs/min (a), 400 pcs/min (b) and 500 pcs/min (c); (n=20). Upper specification limit (USL) = 322.5 mg and lower specification limit (LSL) = 277.5 mg.	143
Figure 4.10	Process capability report for capsule fill weight at 15 mm of dose controller and dosator speed at 300 pcs/min (n=20). Lower specification limit (LSL) = 277.5 mg and Upper specification limit (USL) = 322.5 mg. Solid line curve= overall capability and dash line curve= within capability.	144
Figure 4.11	Process capability report for capsule fill weight at 15 mm of dose controller and dosator speed at 400 pcs/min (n=20). Lower	

	specification limit (LSL) = 277.5 mg and Upper specification limit (USL) = 322.5 mg. Solid line curve= overall capability and dash line curve= within capability.	145
Figure 4.12	Moisture content (%) of FDC CBZ-GBP from the lab scale and pilot scale-up; the latter came from the first batch (Top 1, Middle 1 and Bottom 1) and combined batches (Top 1+2, Middle 1+2 and Bottom 1+2) at different stability time points (month). Real time = RT and accelerated = ACC.	147
Figure 4.13	Carbamazepine content (%) in FDC CBZ-GBP at different stability time point (month). Upper specification limit (USL) = 108% and lower specification limit (LSL) = 92%. ACC = accelerated and RT = real-time.	148
Figure 4.14	Gabapentin content (%) in FDC CBZ-GBP at different stability time point (month). Upper specification limit (USL) = 110% and lower specification limit (LSL) = 90%. ACC = accelerated and RT = real-time.	150
Figure 4.15	Chromatograms of carbamazepine and gabapentin as assayed by HPLC at 0M, 1M RT, 1M ACC, 2M RT, 2M ACC, 3M RT and 3M ACC. Real time = RT, Accelerated = ACC.	152
Figure 4.16	Data represent mean value of 8 samples for disintegration time of FDC CBZ-GBP at different stability time point (month) (n=8). Acceptance criteria is less than 15 minutes based on USP specification.	154
Figure 4.17	Dissolution profile of carbamazepine in FDC CBZ-GBP.	156
Figure 4.18	Dissolution profile of gabapentin in FDC CBZ-GBP.	156

LIST OF EQUATIONS

Equation 2.1	40
Equation 2.2	40
Equation 2.3	40
Equation 2.4	40
Equation 2.5	43
Equation 2.6	45
Equation 2.7	46
Equation 2.8	47
Equation 3.1	93
Equation 3.2	93
Equation 4.1	131

LIST OF ABBREVIATIONS

ACC	Accelerated
ACN	Acetonitrile
ACW	Anti-clockwise
AMD	Analytical Method Development
AMV	Analytical Method Validation
AOR	Angle of Repose
API	Active Pharmaceutical Ingredient
ATR-FTIR	Attenuated Total Reflectance Fourier-Transform Infrared Spectroscopy
AWP	Average Wholesale Price
BBB	Blood Brain Barrier
BCAA	Branched-Chain Amino Acids
BCAA-T	Branched-Chain Amino Acids Transferase
BCS	Biopharmaceutical Classification System
BP	British Pharmacopeia
CBZ	Carbamazepine
CI	Carr Index/ Compressibility Index
CNS	Central Nervous System
CPP	Critical Process Parameters
CQA	Critical Quality Attributes
CSH	Corn starch
CW	Clockwise
DRESS	Drug Rash with Eosinophilia and Systemic Symptoms
DSC	Differential Scanning Calorimetry
FDC	Fixed-Dose Combination
FDC CBZ-GBP	Fixed-Dose Combination of Carbamazepine and Gabapentin
<i>ffc</i>	Flow Function Coefficient
FTIR	Fourier-Transform Infrared Spectroscopy
GABA	γ -aminobutyric acid
GBP	Gabapentin
GC	Gas Chromatography
HCl	Hydrochloric acid
HPLC	High Performance Liquid Chromatography
HPMC	Hydroxypropyl methylcellulose
HR	Hausner ratio
ICH	International Council on Harmonisation
LAC	Lactose monohydrate
LOD	Limit of Detection

LOQ	Limit of Quantification
MAS	Magnesium stearate
MCC	Microcrystalline cellulose
NaOH	Sodium hydroxide
PDPN	Painful Diabetic Peripheral Neuropathy
PPI	Peak Purity Index
PXRD	Powder X-ray Diffraction
QTPP	Quality Target Product Profile
RH	Relative Humidity
RSD	Relative Standard Deviation
RT	Real-time
SD	Standard Deviation
SEM	Scanning Electron Microscopy
TALC	Talc
TDM	Therapeutic Drug Monitoring
TEN	Toxic Epidermal Necrolysis
TG/DTG	Thermo-Gravimetry/Derivative Thermogravimetry
US FDA	United States Food and Drug Administration
USP	United States Pharmacopeia
UV	Ultraviolet
WS	Working standard

CHAPTER ONE

INTRODUCTION

1.1 BACKGROUND OF THE STUDY

Gabapentin (GBP) was first synthesized by Gerhard Satzinger in 1974. It was categorized under biopharmaceutical classification system (BCS) class III (Papich & Martinez, 2015). It was approved by United States Food and Drug Administration (US FDA) in 2002 for nerve-related pain treatment (Kamerman et al., 2016). It has been recommended as one of the first line drugs (Figure 1.1) in the management of peripheral diabetic neuropathy as stated in Malaysia clinical practice guideline (Vijayan et al., 2012). According to the studies conducted in China (Wang et al., 2016), Greece (Athanasakis et al., 2013) and Spain (Rodríguez et al., 2007), pregabalin is more cost-effective than gabapentin for treatment of painful diabetic peripheral neuropathy (PDPN). However, the average wholesale price (AWP) for pregabalin is almost 40-fold higher than gabapentin (Cohen et al., 2015). Therefore, gabapentin remains the drug of choice for PDPN in Malaysia and the tenth most prescribed medication in United States.

Painful diabetic peripheral neuropathy (PDPN) is one of the complications for chronic diabetic patients (Juster-Switlyk & Smith, 2016). The symptoms can be debilitating to the extent that it can cause anxiety, sleep disturbances and reduce mobility (Javed, Alam & Malik, 2015). The treatment management is often challenging and adding up to the number of drugs being taken by chronic diabetic patients. They are usually been prescribed with a number of drugs to treat multiple complications associated with microvascular and macrovascular diseases (Chawla, Chawla & Jaggi, 2016). These treatment complexity could decrease patients' compliance as the number

of drugs and daily doses increase (J. Jin et al., 2008). Therefore, compliance issue due to multiple dosing and polypharmacy attributed to chronic diabetic patient can be minimized by introducing a fixed-dose combination (FDC) of two drugs as shown in Table 1.1.

Most guidelines recommended monotherapy as the first line treatment for neuropathic pain. The examples of drug classes that have consistently shown efficacy against PDPN are anticonvulsants, antidepressants, opioids and local anesthetics. The latest study of PDPN pathophysiology suggested that targeting central and peripheral nervous system simultaneously can improve treatment outcome (Eisenberg & Suzan, 2014). Thus, we hypothesize that combination of two drugs that can bind to the different receptors located at central and peripheral regions may demonstrate better pain relief due to synergistic effect. It was reported earlier in previous study that, the combination of gabapentin and morphine resulted in better analgesia effect at lower doses compared to when given individually (Gilron et al., 2005). However, constipation, sedation, and dry mouth were reported in the subjects. Additionally, the risk of respiratory depression was presented when opioid was given in combination with gabapentin (Kumar et al., 2016). Therefore, the combination of gabapentin and opioid is no longer preferred.

The recent research on the synergistic effect of gabapentin and carbamazepine could be an alternative against trigeminal neuralgia (Matsumoto et al., 2015) and PDPN (Al-Mahmood et al., 2016). In addition, no dosage adjustment and no pharmacokinetic interaction was reported when gabapentin was combined with carbamazepine (Radulovic et al., 1994). Therefore, the idea of combining carbamazepine and gabapentin in one dosage form would be a promising approach to simplify the regime and anticipated to improve patient compliance to the treatment regimen.